In the STEP-4 randomized trial (Rubino and colleagues, JAMA, 2021), the 803 adults who switched to placebo at week 20 regained about 6.9 percent of body weight over the next 48 weeks, while those who continued semaglutide kept losing
\n\n\n\n Research into peripheral nerve healing has been equally compelling
Direct hepatocyte insulin signaling is required for lipogenesis but is dispensable for the suppression of glucose production
Our supplements are always free from unnecessary additives or preservatives and are third-party independently tested
You and your healthcare provider can work together to decide what weight makes sense for your long-term health
Yoo JY, Groer M, Dutra SVO, Sarkar A, McSkimming DI (2020) Gut microbiota and immune system interactions